Brian Park, PharmD

Drug Information Specialist https://www.empr.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Drugs in the Pipeline

Rivaroxaban Plus Aspirin Beneficial in Symptomatic PAD After Revascularization

Brian Park, PharmD

March 30, 2020

Xarelto, a Factor Xa inhibitor, is currently indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

News

Triferic AVNU Approved for Iron Replacement and Hemoglobin Maintenance in Dialysis Patients

Brian Park, PharmD

March 30, 2020

The FDA has approved the New Drug Application for Triferic AVNU®.

News

Taltz Approved for Pediatric Patients with Moderate to Severe Plaque Psoriasis

Brian Park, PharmD

March 27, 2020

The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Drugs in the Pipeline

FDA Accepts XaraColl NDA for Postsurgical Pain After Hernia Surgery

Brian Park, PharmD

March 27, 2020

The FDA has accepted the resubmitted New Drug Application (NDA) for XaraColl® (bupivacaine hydrochloride collagen-matrix implants; Innocoll Holdings Limited) for the management of postsurgical pain after open inguinal hernia surgery.

Safety Alerts and Recalls

Phytonadione Injectable Emulsion Ampules Recalled Following Reports of Glass Injuries

Brian Park, PharmD

March 27, 2020

Dr. Reddy’s Laboratories announced the voluntary recall of 4 lots of Phytonadione Injectable Emulsion 10mg/mL single-dose ampules to the hospital level due to ampules breaking and shattering, upon opening, during compounding.

News

Somryst, A Prescription Digital Therapeutic for Chronic Insomnia, Gets FDA Nod

Brian Park, PharmD

March 27, 2020

The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.

Drugs in the Pipeline

Lower Sodium Oxybate Formulation Gets Priority Review for Narcolepsy

Brian Park, PharmD

March 26, 2020

The FDA has accepted for Priority Review the New Drug Application (NDA) for JZP-258 (Jazz Pharmaceuticals) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy.

News

Potential EpiPen Device Failure, Use Errors Detailed in Letter to HCPs

Brian Park, PharmD

March 25, 2020

Possible device malfunctions and use errors may delay or prevent treatment with EpiPen (epinephrine 0.3mg) and EpiPen Jr (epinephrine 0.15mg) autoinjectors, as well as the authorized generic versions.

News

New Data Show Continued Benefit With Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy

Brian Park, PharmD

March 25, 2020

Patients with spinal muscular atrophy (SMA) treated with a one-time infusion of onasemnogene abeparvovec-xioi (Zolgensma®;AveXis) continue to show clinically meaningful benefits even 5 years after dosing.

Drugs in the Pipeline

Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status

Brian Park, PharmD

March 25, 2020

The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.